Cargando…

Role of capecitabine in treating metastatic colorectal cancer in Chinese patients

The China Food and Drug Administration approved the use of capecitabine in patients with metastatic colorectal cancer (mCRC) in 2004. This paper reviews the available information of capecitabine in Chinese patients with mCRC, focusing on its effectiveness and safety against mCRC. Identification of a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Feng, Wang, Feng-Hua, Bai, Long, Xu, Rui-Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979786/ https://www.ncbi.nlm.nih.gov/pubmed/24729715 http://dx.doi.org/10.2147/OTT.S38843

Ejemplares similares

Capecitabine in the management of colorectal cancer
por: Hirsch, Bradford R, et al.
Publicado: (2011)

A review of the role of capecitabine in the treatment of colorectal cancer
por: Comella, Pasquale
Publicado: (2007)

Metronomic chemotherapy with capecitabine for metastatic colorectal cancer in very elderly patients
por: Jung, Yun Hwa, et al.
Publicado: (2017)

Milk and Egg Are Risk Factors for Adverse Effects of Capecitabine-Based Chemotherapy in Chinese Colorectal Cancer Patients
por: Xu, Jinrong, et al.
Publicado: (2022)

Traditional Chinese medicines and capecitabine‐based chemotherapy for colorectal cancer treatment: A meta‐analysis
por: Jiang, Hui‐Zhong, et al.
Publicado: (2022)

Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients
por: Geng, Rui, et al.
Publicado: (2020)

Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer
por: Dong, Si-Qi, et al.
Publicado: (2021)

Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Alliot, C
Publicado: (2006)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
por: Li, Wenhua, et al.
Publicado: (2014)

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer
por: Ward, S E, et al.
Publicado: (2006)

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer
por: Almond, J, et al.
Publicado: (2007)

Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane
por: Ahn, Jin-Hee, et al.
Publicado: (2004)

Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2016)

Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2006)

Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2011)

Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
por: Molina-Garrido, M J, et al.
Publicado: (2011)

Fecal levels of SCFA and BCFA during capecitabine in patients with metastatic or unresectable colorectal cancer
por: Ziemons, Janine, et al.
Publicado: (2023)

Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women
por: Su, Jinsong, et al.
Publicado: (2019)

Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Reply: The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer
por: Ward, S E
Publicado: (2007)

Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World Study
por: Leicher, Laura W., et al.
Publicado: (2016)

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
por: Saura, Cristina, et al.
Publicado: (2021)

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
por: Boisen, Mogens K., et al.
Publicado: (2014)

Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer
por: Munemoto, Yoshinori, et al.
Publicado: (2015)

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
por: LIANG, XU, et al.
Publicado: (2015)

Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
por: García-Alfonso, P, et al.
Publicado: (2010)

Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: A systematic review and meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2019)

A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer
por: Bai, Long, et al.
Publicado: (2015)

Erratum to: Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial
por: Xu, Jianming, et al.
Publicado: (2020)

Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients
por: Stavraka, Chara, et al.
Publicado: (2019)

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2005)

Survival effect of probiotics in a rat model of colorectal cancer treated with capecitabine
por: Gigola, Graciela, et al.
Publicado: (2021)

Targeting cancers in the gastrointestinal tract: role of capecitabine
por: Saif, Muhammad Wasif
Publicado: (2009)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response
por: Li, Zhe-Zhen, et al.
Publicado: (2016)

Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer
por: Si, W., et al.
Publicado: (2013)

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
por: Garcia-Alfonso, Pilar, et al.
Publicado: (2015)

Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study
por: Kibudde, Solomon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a82ib3ggaqoqjqlcd1suma70od